Alector

ALEC · NASDAQ

$1.97+$0.02 (+1.03%)TodayMarket closed · Oct 20, 7:58 PM ET

Prev close $1.95

ALEC analyst rating

HoldConsensus of 7 analysts over the last 12 months. 57% rate it a buy.

Strong buy0
Buy4
Hold2
Underperform1
Sell0

12-month price target · 7 analysts

Average $3.16 (+60.5% upside)

Low: $1.01
Now: $1.97
High: $6.30

Upgrades and downgrades

The latest rating actions, newest first

ALEC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Oct 15, 2026	Maintains	Buy	$5.00 → $8.00	54%
HC Wainwright & Co.	Oct 14, 2026	Maintains	Buy	$5.00 → $8.00	54%
Morgan Stanley	Oct 6, 2026	Maintains	Underweight	$2.00 → $3.00	47%
Cantor Fitzgerald	Apr 15, 2026	Upgrade	Neutral → Overweight	—	28%
BTIG	Mar 10, 2026	Upgrade	Neutral → Buy	$6.00	30%
TD Cowen	Oct 22, 2025	Downgrade	Buy → Hold	—	49%
Cantor Fitzgerald	Oct 22, 2025	Downgrade	Overweight → Neutral	—	28%
HC Wainwright & Co.	Oct 22, 2025	Maintains	Buy	$10.00 → $5.00	50%
William Blair	Oct 22, 2025	Downgrade	Outperform → Market Perform	—	55%
BTIG	Oct 22, 2025	Downgrade	Buy → Neutral	—	30%

The case for and against

Updated Oct 17, 2026

Bull case

Alector is compelling because its ABC blood-brain barrier shuttle could turn the company from a single-asset antibody story into a broader platform for antibody, enzyme, and siRNA delivery across neurodegenerative diseases. The pipeline is strengthened by validated biology and differentiation, including AL137’s 29–32x higher brain exposure in NHPs versus naked antibody, AL050’s Genentech licensing signal, and potent siRNA knockdown data of 58–76% for MAPT and 76–94% for SNCA. Although AL137 still faces clinical execution risk, the 3Q27 healthy-volunteer safety readout offers a clear upcoming catalyst, while the platform’s targeted delivery and cleaner reticulocyte profile could support multiple shots on goal.

Bear case

Alector is still fundamentally exposed to classic clinical-stage biotech risk: its value depends on AL137, AL164, AL062, and AL050 advancing successfully through preclinical and clinical studies and then obtaining regulatory approval in the US and EU. Although the $100M AL050 upfront from Genentech and risk-adjusted milestones and royalties improve liquidity and support the model, the company remains dependent on unproven programs and updated AL137 launch assumptions rather than recurring commercial cash flow. The cited valuation framework also highlights fragility, with only $0.67 of taxed and diluted FY36 GAAP EPS discounted back to FY26 and an NPV that assumes peak revenue achievement, making downside significant if market size, penetration, or pricing disappoints.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.